ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1 ,Andrews Annan E. 2 , Koduah A. 1 , Asare A.B. 1 1 Ghana National Drugs Programme 2 World Health Organisation/Ghana
Jan 13, 2016
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN
GHANAAuthors: Gyansa-Lutterodt M.1,Andrews Annan E.2, Koduah A.1, Asare A.B.1
1 Ghana National Drugs Programme 2 World Health Organisation/Ghana
##
#
#
##
#
#
#
#
#
#
#
#
##
#
#
#
#
#
#
#
#
#
##
#
# ##
#
##
#
##
#
#
#
#
#
##
#
#
#
##
#
#
#
#
#
#
#
#
#
#
#
#
##
#
#
#
#
#
#
#
#
#
## #
#
#
###
#
#
#
#
##
#
#
#
#
##
#
#
#
#
#
#
#
#
#
#
##
#
#
#
#
#
#
#Y
#Y
#Y
#Y
#Y
#Y
#Y
#Y
#Y
#Y
LAWRA
LAWRA
TUMU
NADAWLI
WA
SANDEMA
NAVRONGO
BOLGATANGA
BONGO ZEBILLA
GAMBAGA
WALEWALE
BAWKU
TOLON TAMALE
SAVELUGU
GUSHIEGU
YENDI
SABOBA
ZABZUGU
BIMBILA
DAMONGOBOLE
SALAGA
KINTAMPO
ATEBUBU KWAME DANSO
NKORANZATECHIMAN
WENCHI
EJURASUNYANI
DROBO
BEREKUM
DORMAA AHENKRO
BECHEM
KENYASE NO. 1TEPA OFINSO
AGONA AKROFOSO
EFFIDUASEMAMPONTENG
MANKRANSOGOASO
KUMASI EJISUNKAWIE
KUNTENASE
KONONGO-ODUMASE
JUASO
BEKWAIMANSO NKWANTA
MAMPONG ASHANTI
OBUASI
NEW EDUBIASE
NEW ABIREM
MPRAESO
BEGORO
KIBIKADE
AKIM ODAASAMANKESE
SUHUM
KOFORIDUA ODUMASE KROBOSOMANYA
ATIMPOKU
AKROPONG AKWAPIM
DODOWA
NSAWAM
AMASAMAN
ACCRATEMA MUNICIPAL AREA
AGONA SWEDRU
WINNEBAAPAM
SALTPOND
CAPE COASTELMINA
DABOASE
TWIFO PRASO
ASSIN FOSU
AJUMAKO
BREMAN ASIKUMA
ABURA DUNKWA
HO
DUNKWA-ON-OFIN
TARKWA
SEKONDI/ TAKORADIAGONA NKWANTAAXIM
HALF ASSINI
ASANKRAGUA
SEFWI WIAWSO
JUABESO
ENCHI
BIBIANI
AKATSIDENU
ADA FOAH
SOGAKOPEADIDOME
KPANDU
KADJEBI
JASIKAN
HOHOEDONKORKROM
KETE-KRACHI
NKWANTA
Upper West
Upper East
Northern
Brong Ahafo
Ashanti
VoltaEastern
Western
Central Greater Accra
RegionsAshantiBrong AhafoCentralEasternGreater AccraNorthernUpper EastUpper WestVoltaWestern
Water body# District Capital#Y Regional Capital
Ghana boundary
200 0 200 400 KilometersN
EW
S
Ghana Map
Prepared by Alexander Boakye Marful, July 2005
• Equitable access to essential medicines for children and their rational use is a preceding step in achieving the country and global targets on child mortality.
• Infant and under five mortality rates are estimated at 50 and 80 respectively per 1000 births in Ghana.
• Ghana’s under 5 mortality remains high (111/1000 live births in 2001-2006). Declines in mortality that began in the 1980’s have slowed.
• Most of these deaths are preventable by access to safe essential child-specific medicines with the necessary framework for their rational use.
Introduction
BUKINA FASO
TOGOCOTE
D’IVOIRE
A T L A N T I C O C E A N
Regional Population (2010 Census)
Region Population % of Total Population
Upper West 677,763 2.8%
Upper East 1,031,478 4.3%
Northern 2,468,557 10.2%
Brong-Ahafo 2,282,128 9.4%
Ashanti 4,725,046 19.5%
Western 2,325,597 9.6%
Central 2,107,209 8.7%
Eastern 2,596,013 10.7%
Greater Accra 3,909,764 16.1%
Volta 2,099,876 8.7%
National 24,223,431 100%Under 18 (est.) 11,505,050 47.5%
18 – 69 (est.) 12,075,513 49.8%
70 & above (est.) 652,868 2.7%
Source: Ghana Statistical Service. Provisional results of 2010 Census
High infant and under 5 child mortality
Known causes of death
Malaria25%
Neonatal causes27%
Diarrhoea17%
Pneumonia20%
Measles3%
HIV/AIDS8%
The Better Medicines for Children Project• The BMC project, initiated by the World Health
Organization in 2009 with funding from the Bill and Melinda Gates Foundation seeks to increase access to child specific medicines within the framework of existing country policy.
• The project is also to support country efforts to achieve the Millennium Development Goals (Goals Four and Six).
• The Better Medicines for Children (BMC) project is implemented in Ghana through the Ghana National Drugs Programme of the Ministry of Health.
Strategic Objectives of the BMC Project
• Promoting access to essential medicines for children• Advocating for their inclusion in national essential
medicines lists, treatment guidelines, NHI and procurement schemes with policy makers.
• Working with drug regulatory authorities to expedite regulatory actions on selected medicines for children;
• Developing measures to monitor and manage their prices.
• Measure the availability of child-specific medicines in Ghana;
• Evaluate and compare prices of child-specific medicines in the public, private and mission sectors to government procurement prices;
• Evaluate the affordability of child-specific medicines in Ghana.
Objectives of the study
• The survey of medicine prices and availability was conducted in three regions, namely: Greater Accra, Ashanti and Upper West Regions.
• Data on 30 child-specific medicines (38 formulations) were collected in 18 public and 42 private sector medicine outlets (including four mission drug outlets).
• Data was also collected on government procurement prices for the selected medicines.
• For each medicine in the survey, data was collected for the originator brand and lowest-priced generic equivalent (i.e. generic product with the lowest price at each facility).
• Medicine prices were expressed as ratios relative to Management Sciences for Health international reference prices for 2009 (Median Price Ratio).
Methods
Graph of Mean availability of medicines on the day of data collection, public, private and mission sectors
Results
PUBLIC SECTOR PRICES
Public sector procurement - ratio of median unit price to MSH international reference price (median price ratio or MPR)
Public sector patient prices - ratio of median unit price to MSH international reference price (median price ratio or MPR)
Results
Median MPRs for medicines found in both public procurement and public sector medicine outlets (final patient prices)
PRIVATE SECTOR PATIENT PRICES Ratio of median unit price to MSH international reference price (median price ratio or MPR)
Results
MISSION SECTOR PATIENT PRICESRatio of median unit price to MSH international reference
price(median price ratio or MPR), median for all medicines found
Results
Results
Number of day’s wages required to treat selected uncomplicated conditions based on standard treatments
Summary of Results- Public Sector• Availability of medicines in the public
– Mean availability of originator brand and generic medicines in the public sector was 2.7% and 19.3 %, respectively.
• Public sector procurement prices– In the public sector, the central medical store (CMS) is purchasing
medicines at prices 1.43 times (at a MPR of 1.43) higher than international reference prices, indicating a reasonable level of purchasing efficiency.
• Public sector patient prices– Final patient prices for generic medicines in the public sector are
about three times higher than their international reference prices.– Public sector patient prices for generic medicines are 101.9 %
higher than those for public procurement , indicating the extent of mark-ups in the public sector distribution chain.
Summary of Results- Private Sector• Availability in the Private Sector
– the mean availability of originator brand and generic medicines was 9.0% and 17.4% for the private sector and 4.6% and 21.7% for the mission sector, respectively.
• Private sector patient prices:– Final patient prices for originator brands and lowest-priced generics in
the private sector are about 11.06 and 3.37 times their international reference prices, respectively.
• Affordability of standard treatment regimens:– In treating common conditions using a standard regimen, the lowest-
paid government worker would need between 0.2 (diarrhoea), 0.6 (moderate pneumonia), and 1.3 (malaria) day’s wages to purchase lowest-priced generic medicines from the private sector.
Summary of Results- Mission Sector
• The results obtained from the Mission sector were not very different from those obtained in the public sector– Most of the mission sector facilities obtain their
medicines from the public sector warehouses
Conclusions • The survey results show that availability of child-
specific medicines is very low across sectors in Ghana.
• While the availability of originator brand medicines is low in all sectors, when these are found in the private sector they cost over three times more than their generic equivalents.
• In public, private and mission sectors, even lowest-priced generics cost over three times their international reference price, on average.
Recommendations • The national medicines selection process should be made
child-medicines sensitive. • These medicines should be listed on the national EML and on
the NHIA reimbursement list to ensure subsequent procurement, distribution and reimbursement.
• The private wholesalers and distributors should also be engaged to procure child-specific medicines as part of their product lines. Thus the private sector supply chain can augment efforts in the public supply system.
• Prescribers and dispensers should be informed about available child-specific formulations to ensure the prescription and dispensing of appropriate formulations. There is existing opportunity within the DTC framework to support such action.
Research gap
• What factors contribute to low availability of child specific medicines in Ghana?– Medicines not listed on EML/NHIML– Profits– Interest of wholesalers– Local Manufacturer capability/capacity– Lack of availability on global markets
• THANK YOU FOR YOUR ATTENTION